Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02694185 · ClinicalTrials.gov registry record · NA
Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications
A NA study of Myocardial Ischemia and Rheumatic Diseases, sponsored by VA Office of Research and Development.
- Active
- Registry status
- NA
- Development phase
- 5,269
- Enrollment target
- 5
- Study locations
NCT02694185 is a NA study of Myocardial Ischemia and Rheumatic Diseases that is active but no longer recruiting, run by VA Office of Research and Development. The registered enrollment target is 5,269 participants, above the 1,956-participant average among 29 other Myocardial Ischemia trials with a reported enrollment target (169% higher). The trial reports 5 study locations across 5 states.
The verdict
NCT02694185, a NA study of Myocardial Ischemia and Rheumatic Diseases, is active but no longer recruiting, sponsored by VA Office of Research and Development.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 5,269 participants
- Enrollment target
- 5
- Study locations
Study Summary
Ischemic heart disease (IHD) and its treatment carry profound public health and economic implications. Among Veterans, IHD represents one of the most common causes of death and disability, with over 500,000 affected individuals' annually. Rheumatic disease, though far less common than IHD can affect multiple organ systems and requires therapies costing in excess of $50,000 a year. Optimal treatment of Veterans with IHD and rheumatic disease requires a number of medications to maintain or improve health. Not taking medications as prescribed, however, is common and increases the risk of subsequent adverse events (cardiac death and myocardial infarction \[MI\]). To improve medication adherence rates and the cardiac health of Veterans with IHD, the investigators propose to test a medication adherence intervention. Known as VA SEPPRMACI-ARM (Secondary Event Prevention using Population Risk Management After PCI and for Anti-Rheumatic Medications), this intervention will consist of: proactive real-time adherence monitoring of patients and targeting of individuals if they have not refilled their medication a given number of days after it was due for refill. The intervention will employ a tailored, escalating-intensity approach which begins with some combination of personalized short messaging service (SMS) text messages and interactive voice response (IVR) telephone technology, depending on patient preference. Patients not completing SMS and then IVR by not refilling their medication (or declining SMS and not completing IVR) escalate to a trained research interventionalist. The interventionalist will contact the patient and address adherence barriers based on the dimensions outlined by the World Health Organization (WHO) that are specific to each patient. The investigators will test the intervention on IHD patients who have recently undergone PCI-a cardiac procedure commonly used among IHD patients to improve the heart's blood flow and in patients starting anti-rheumatic m
Conditions Studied
Interventions
- OTHER Caplan IVR
Study Locations (5)
California
- San Francisco VA Medical Center, San Francisco, CA - San Francisco
Colorado
- Rocky Mountain Regional VA Medical Center, Aurora, CO - Aurora
Maryland
- Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD - Baltimore
North Carolina
- Durham VA Medical Center, Durham, NC - Durham
Other
- VA Caribbean Healthcare System, San Juan, PR - San Juan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,269 participants |
| Start Date | 2016-10-01 |
| Est. Completion | 2025-02-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02694185
The ClinicalTrials.gov registry entry for NCT02694185 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 5,269 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,956-participant average among 29 other Myocardial Ischemia trials with a reported enrollment target (169% higher). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Myocardial Ischemia appearing as the primary indexed condition, and to 1 intervention - of which Caplan IVR is the first listed.
NCT02694185 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Colorado, Maryland.
Frequently Asked Questions
What is clinical trial NCT02694185 about?
NCT02694185 is a clinical study titled "Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications". Ischemic heart disease (IHD) and its treatment carry profound public health and economic implications. Among Veterans, IHD represents one of the most common causes of death and disability, with over 500,000 affected individuals' annually. Rheumatic disease, though far less common than IHD can affect...
What is the current status of trial NCT02694185?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 5,269 participants. The study started on 2016-10-01. Estimated completion is 2025-02-28.
What conditions does trial NCT02694185 study?
This clinical trial studies the following conditions: Myocardial Ischemia, Rheumatic Diseases.
What interventions are being tested in trial NCT02694185?
The interventions under investigation include: Caplan IVR (OTHER).
Who is sponsoring clinical trial NCT02694185?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02694185 being conducted?
This trial has 5 study locations across California, Colorado, Maryland, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myocardial Ischemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bright Light Exposure in Surgical Patients
RECRUITING · NA
-
A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)
RECRUITING · NA
-
Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II
RECRUITING · NA
-
A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction
ACTIVE NOT RECRUITING · NA
-
Clinical Evaluation of Cardiac Output Estimation Based on Pulse Wave Transit Time
COMPLETED · NA
-
Sapphire 3 CTO Study
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.